{"status":"ok","message-type":"work","message-version":"1.0.0","message":{"indexed":{"date-parts":[[2026,5,20]],"date-time":"2026-05-20T15:36:47Z","timestamp":1779291407319,"version":"3.51.4"},"reference-count":45,"publisher":"Springer Science and Business Media LLC","issue":"9","license":[{"start":{"date-parts":[[2021,7,16]],"date-time":"2021-07-16T00:00:00Z","timestamp":1626393600000},"content-version":"tdm","delay-in-days":0,"URL":"https:\/\/www.springer.com\/tdm"},{"start":{"date-parts":[[2021,7,16]],"date-time":"2021-07-16T00:00:00Z","timestamp":1626393600000},"content-version":"vor","delay-in-days":0,"URL":"https:\/\/www.springer.com\/tdm"}],"content-domain":{"domain":["link.springer.com"],"crossmark-restriction":false},"short-container-title":["Curr Oncol Rep"],"published-print":{"date-parts":[[2021,9]]},"DOI":"10.1007\/s11912-021-01094-y","type":"journal-article","created":{"date-parts":[[2021,7,16]],"date-time":"2021-07-16T15:03:01Z","timestamp":1626447781000},"update-policy":"https:\/\/doi.org\/10.1007\/springer_crossmark_policy","source":"Crossref","is-referenced-by-count":11,"title":["Leukemic Variant of Mantle Cell Lymphoma: Clinical Presentation and Management"],"prefix":"10.1007","volume":"23","author":[{"given":"Krista M.","family":"Isaac","sequence":"first","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Craig A.","family":"Portell","sequence":"additional","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Michael E.","family":"Williams","sequence":"additional","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]}],"member":"297","published-online":{"date-parts":[[2021,7,16]]},"reference":[{"key":"1094_CR1","unstructured":"Swerdlow SH, Campo E, Seto M, Muller-Hermelink H. Mantle cell lymphoma. WHO Classif Tumours Haematop Lymphoid Tissues, revised 4th Ed. 2017. p. 285\u201390."},{"key":"1094_CR2","doi-asserted-by":"publisher","first-page":"1387","DOI":"10.1182\/blood.V76.7.1387.1387","volume":"76","author":"ME Williams","year":"1990","unstructured":"Williams ME, Westermann CD, Swerdlow SH. Genotypic characterization of centrocytic lymphoma: frequent rearrangement of the chromosome 11 bcl-1 locus. Blood. 1990;76:1387\u201391. https:\/\/doi.org\/10.1182\/blood.V76.7.1387.1387.","journal-title":"Blood"},{"key":"1094_CR3","doi-asserted-by":"publisher","first-page":"493","DOI":"10.1182\/blood.V78.2.493.493","volume":"78","author":"ME Williams","year":"1991","unstructured":"Williams ME, Meeker TC, Swerdlow SH. Rearrangement of the chromosome 11 bcl-1 locus in centrocytic lymphoma: analysis with multiple breakpoint probes. Blood. United States. 1991;78:493\u20138.","journal-title":"Blood"},{"key":"1094_CR4","doi-asserted-by":"publisher","first-page":"637","DOI":"10.1097\/00000478-199207000-00001","volume":"16","author":"PM Banks","year":"1992","unstructured":"Banks PM, Chan J, Cleary ML, Delsol G, De Wolf-Peeters C, Gatter K, et al. Mantle cell lymphoma. A proposal for unification of morphologic, immunologic, and molecular data. Am J Surg Pathol. United States. 1992;16:637\u201340.","journal-title":"Am J Surg Pathol"},{"key":"1094_CR5","doi-asserted-by":"publisher","first-page":"999","DOI":"10.1016\/0046-8177(95)90090-X","volume":"26","author":"SH Swerdlow","year":"1995","unstructured":"Swerdlow SH, Yang WI, Zukerberg LR, Harris NL, Arnold A, Williams ME. Expression of cyclin D1 protein in centrocytic\/mantle cell lymphomas with and without rearrangement of the BCL1\/cyclin D1 gene. Hum Pathol. United States. 1995;26:999\u20131004.","journal-title":"Hum Pathol"},{"key":"1094_CR6","doi-asserted-by":"publisher","first-page":"1419","DOI":"10.1182\/blood.2020005289","volume":"136","author":"F Nadeu","year":"2020","unstructured":"\u2022\u2022 Nadeu F, Martin-Garcia D, Clot G, D\u00edaz-Navarro A, Duran-Ferrer M, Navarro A, et al. Genomic and epigenomic insights into the origin, pathogenesis, and clinical behavior of mantle cell lymphoma subtypes. Blood. 2020;136:1419\u201332. https:\/\/doi.org\/10.1182\/blood.2020005289This study performed whole exome sequencing and epigenomic analysis on cMCL and LV-MCL patient samples to demonstrate the distinct phenotypes of the two subsets.","journal-title":"Blood"},{"key":"1094_CR7","doi-asserted-by":"publisher","first-page":"1378","DOI":"10.1182\/blood.2020006581","volume":"136","author":"B Sander","year":"2020","unstructured":"Sander B. Under the cover of mantle cell lymphoma. Blood. United States. 2020;136:1378\u20139.","journal-title":"Blood"},{"key":"1094_CR8","doi-asserted-by":"publisher","first-page":"50","DOI":"10.1038\/s41408-019-0209-5","volume":"9","author":"A Kumar","year":"2019","unstructured":"Kumar A, Sha F, Toure A, Dogan A, Ni A, Batlevi CL, et al. Patterns of survival in patients with recurrent mantle cell lymphoma in the modern era: progressive shortening in response duration and survival after each relapse. Blood Cancer J. 2019;9:50. https:\/\/doi.org\/10.1038\/s41408-019-0209-5.","journal-title":"Blood Cancer J"},{"key":"1094_CR9","doi-asserted-by":"publisher","first-page":"697","DOI":"10.1007\/s00428-016-2016-8","volume":"469","author":"M Gallo","year":"2016","unstructured":"Gallo M, Cacheux V, Vincent L, Bret C, Tempier A, Guittard C, et al. Leukemic non-nodal mantle cell lymphomas have a distinct phenotype and are associated with deletion of PARP1 and 13q14. Virchows Arch. Germany. 2016;469:697\u2013706.","journal-title":"Virchows Arch"},{"key":"1094_CR10","doi-asserted-by":"publisher","first-page":"149","DOI":"10.1111\/j.1365-2141.2008.07124.x","volume":"142","author":"P Jares","year":"2008","unstructured":"Jares P, Campo E. Advances in the understanding of mantle cell lymphoma. Br J Haematol. England. 2008;142:149\u201365.","journal-title":"Br J Haematol"},{"key":"1094_CR11","doi-asserted-by":"publisher","first-page":"1408","DOI":"10.1158\/0008-5472.CAN-09-3419","volume":"70","author":"V Fern\u00e0ndez","year":"2010","unstructured":"Fern\u00e0ndez V, Salamero O, Espinet B, Sol\u00e9 F, Royo C, Navarro A, et al. Genomic and gene expression profiling defines indolent forms of mantle cell lymphoma. Cancer Res. United States. 2010;70:1408\u201318.","journal-title":"Cancer Res"},{"key":"1094_CR12","doi-asserted-by":"publisher","first-page":"1121","DOI":"10.3324\/haematol.2010.036277","volume":"96","author":"SL Ondrejka","year":"2011","unstructured":"Ondrejka SL, Lai R, Smith SD, Hsi ED. Indolent mantle cell leukemia: a clinicopathological variant characterized by isolated lymphocytosis, interstitial bone marrow involvement, kappa light chain restriction, and good prognosis. Haematologica. 2011;96:1121\u20137.","journal-title":"Haematologica."},{"key":"1094_CR13","doi-asserted-by":"publisher","first-page":"43","DOI":"10.1007\/s11912-017-0598-1","volume":"19","author":"S Be\u00e0","year":"2017","unstructured":"Be\u00e0 S, Amador V. Role of SOX11 and genetic events cooperating with cyclin D1 in mantle cell lymphoma. Curr Oncol Rep. United States. 2017;19:43.","journal-title":"Curr Oncol Rep"},{"key":"1094_CR14","doi-asserted-by":"publisher","first-page":"1212","DOI":"10.1016\/j.leukres.2009.01.017","volume":"33","author":"GA Palumbo","year":"2009","unstructured":"Palumbo GA, Parrinello N, Fargione G, Cardillo K, Chiarenza A, Berretta S, et al. CD200 expression may help in differential diagnosis between mantle cell lymphoma and B-cell chronic lymphocytic leukemia. Leuk Res. England. 2009;33:1212\u20136.","journal-title":"Leuk Res"},{"key":"1094_CR15","doi-asserted-by":"publisher","first-page":"800","DOI":"10.1182\/blood-2007-06-093401","volume":"111","author":"S Ek","year":"2008","unstructured":"Ek S, Dictor M, Jerkeman M, Jirstr\u00f6m K, Borrebaeck CAK. Nuclear expression of the non B-cell lineage Sox11 transcription factor identifies mantle cell lymphoma. Blood. United States. 2008;111:800\u20135.","journal-title":"Blood"},{"key":"1094_CR16","doi-asserted-by":"publisher","first-page":"248","DOI":"10.1111\/j.1365-2141.2008.07329.x","volume":"143","author":"X Wang","year":"2008","unstructured":"Wang X, Asplund AC, Porwit A, Flygare J, Smith CIE, Christensson B, et al. The subcellular Sox11 distribution pattern identifies subsets of mantle cell lymphoma: correlation to overall survival. Br J Haematol. England. 2008;143:248\u201352.","journal-title":"Br J Haematol"},{"key":"1094_CR17","doi-asserted-by":"publisher","first-page":"1555","DOI":"10.3324\/haematol.2009.010264","volume":"94","author":"A Mozos","year":"2009","unstructured":"Mozos A, Royo C, Hartmann E, De Jong D, Bar\u00f3 C, Valera A, et al. SOX11 expression is highly specific for mantle cell lymphoma and identifies the cyclin D1-negative subtype. Haematologica. 2009;94:1555\u201362.","journal-title":"Haematologica."},{"key":"1094_CR18","doi-asserted-by":"crossref","unstructured":"Royo C, Navarro A, Clot G, Salaverria I, Gin\u00e9 E, Jares P, et al. Non-nodal type of mantle cell lymphoma is a specific biological and clinical subgroup of the disease. Leukemia. 2012;1895\u20138.","DOI":"10.1038\/leu.2012.72"},{"key":"1094_CR19","doi-asserted-by":"publisher","first-page":"299","DOI":"10.1097\/MOH.0000000000000434","volume":"25","author":"R Beekman","year":"2018","unstructured":"Beekman R, Amador V, Campo E. SOX11, a key oncogenic factor in mantle cell lymphoma. Curr Opin Hematol. United States. 2018;25:299\u2013306.","journal-title":"Curr Opin Hematol"},{"key":"1094_CR20","doi-asserted-by":"publisher","first-page":"306","DOI":"10.1182\/blood-2018-05-851667","volume":"133","author":"A Mohanty","year":"2019","unstructured":"Mohanty A, Sandoval N, Phan A, Nguyen TV, Chen RW, Budde E, et al. Regulation of SOX11 expression through CCND1 and STAT3 in mantle cell lymphoma. Blood. 2019;133:306\u201318.","journal-title":"Blood."},{"key":"1094_CR21","doi-asserted-by":"publisher","first-page":"1865","DOI":"10.3324\/haematol.2009.019745","volume":"95","author":"F Baran-Marszak","year":"2010","unstructured":"Baran-Marszak F, Boukhiar M, Harel S, Laguillier C, Roger C, Gressin R, et al. Constitutive and B-cell receptor-induced activation of STAT3 are important signaling pathways targeted by bortezomib in leukemic mantle cell lymphoma. Haematologica. 2010;95:1865\u201372.","journal-title":"Haematologica."},{"key":"1094_CR22","doi-asserted-by":"publisher","first-page":"3416","DOI":"10.1172\/JCI61272","volume":"122","author":"P Jares","year":"2012","unstructured":"Jares P, Colomer D, Campo E. Molecular pathogenesis of mantle cell lymphoma. J Clin Invest. 2012;122:3416\u201323.","journal-title":"J Clin Invest."},{"key":"1094_CR23","doi-asserted-by":"crossref","unstructured":"\u2022\u2022 Puente XS, Jares P, Campo E. Chronic lymphocytic leukemia and mantle cell lymphoma: crossroads of genetic and microenvironment interactions. Blood. United States; 2018;131:2283\u201396. In this review article, the authors compare CLL and MCL, and highlight differences in pathogenesis and clinical evolution. The overlap between genetic driver and actional targets is also discussed.","DOI":"10.1182\/blood-2017-10-764373"},{"key":"1094_CR24","doi-asserted-by":"publisher","first-page":"185","DOI":"10.1186\/s13046-017-0652-8","volume":"36","author":"H Ye","year":"2017","unstructured":"Ye H, Desai A, Zeng D, Nomie K, Romaguera J, Ahmed M, et al. Smoldering mantle cell lymphoma. J Exp Clin Cancer Res. 2017;36:185.","journal-title":"J Exp Clin Cancer Res."},{"key":"1094_CR25","doi-asserted-by":"publisher","first-page":"5307","DOI":"10.1158\/0008-5472.CAN-12-1615","volume":"72","author":"A Navarro","year":"2012","unstructured":"Navarro A, Clot G, Royo C, Jares P, Hadzidimitriou A, Agathangelidis A, et al. Molecular subsets of mantle cell lymphoma defined by the IGHV mutational status and SOX11 expression have distinct biologic and clinical features. Cancer Res. 2012;72:5307\u201316.","journal-title":"Cancer Res."},{"key":"1094_CR26","doi-asserted-by":"publisher","first-page":"710","DOI":"10.1097\/PAS.0000000000001233","volume":"43","author":"J Xu","year":"2019","unstructured":"Xu J, Wang L, Li J, Saksena A, Wang SA, Shen J, et al. SOX11-negative mantle cell lymphoma: clinicopathologic and prognostic features of 75 patients. Am J Surg Pathol. United States. 2019;43:710\u20136.","journal-title":"Am J Surg Pathol"},{"key":"1094_CR27","doi-asserted-by":"crossref","unstructured":"\u2022\u2022 Saksena A, Yin CC, Xu J, Li J, Zhou J, Wang SA, et al. CD23 expression in mantle cell lymphoma is associated with CD200 expression, leukemic non-nodal form, and a better prognosis. Hum Pathol. United States; 2019;89:71\u201380. In this study, 798 MCL samples were evaluated;103 samples were CD23-positive. The authors then described the clinical disease course for CD23-positive patients as compared to CD23-negative patients, demonstrating that CD23-positive MCL more frequently presents in a leukemic form with indolent disease course.","DOI":"10.1016\/j.humpath.2019.04.010"},{"key":"1094_CR28","doi-asserted-by":"publisher","first-page":"837","DOI":"10.1309\/AJCPBV9ELXC0ECVL","volume":"142","author":"P Challagundla","year":"2014","unstructured":"Challagundla P, Medeiros LJ, Kanagal-Shamanna R, Miranda RN, Jorgensen JL. Differential expression of CD200 in B-cell neoplasms by flow cytometry can assist in diagnosis, subclassification, and bone marrow staging. Am J Clin Pathol. England. 2014;142:837\u201344.","journal-title":"Am J Clin Pathol"},{"key":"1094_CR29","doi-asserted-by":"crossref","unstructured":"Debord C, Robillard N, Theisen O, Gastinne T, Godmer P, Graveleau J, et al. CD200 expression in flow cytometry helps to distinguish mantle cell lymphoma from other CD5-positive B-cell neoplasms. Hematol. Oncol. England; 2018.","DOI":"10.1002\/hon.2511"},{"key":"1094_CR30","doi-asserted-by":"publisher","first-page":"327","DOI":"10.1038\/modpathol.2017.135","volume":"31","author":"Z Hu","year":"2018","unstructured":"Hu Z, Sun Y, Schlette EJ, Tang G, Li S, Xu J, et al. CD200 expression in mantle cell lymphoma identifies a unique subgroup of patients with frequent IGHV mutations, absence of SOX11 expression, and an indolent clinical course. Mod Pathol an Off J United States Can Acad Pathol Inc. United States. 2018;31:327\u201336.","journal-title":"Mod Pathol an Off J United States Can Acad Pathol Inc"},{"key":"1094_CR31","doi-asserted-by":"publisher","first-page":"3329","DOI":"10.3109\/10428194.2015.1030642","volume":"56","author":"L Fan","year":"2015","unstructured":"Fan L, Miao Y, Wu Y-J, Wang Y, Guo R, Wang L, et al. Expression patterns of CD200 and CD148 in leukemic B-cell chronic lymphoproliferative disorders and their potential value in differential diagnosis. Leuk Lymphoma. United States. 2015;56:3329\u201335.","journal-title":"Leuk Lymphoma"},{"key":"1094_CR32","doi-asserted-by":"publisher","first-page":"4975","DOI":"10.1182\/blood-2002-06-1864","volume":"101","author":"J Orchard","year":"2003","unstructured":"Orchard J, Garand R, Davis Z, Babbage G, Sahota S, Matutes E, et al. A subset of t(11;14) lymphoma with mantle cell features displays mutated IgVH genes and includes patients with good prognosis, nonnodal disease. Blood. United States. 2003;101:4975\u201381.","journal-title":"Blood"},{"key":"1094_CR33","doi-asserted-by":"publisher","first-page":"2007","DOI":"10.1080\/10428190410001723331","volume":"45","author":"E Matutes","year":"2004","unstructured":"Matutes E, Parry-Jones N, Brito-Babapulle V, Wotherspoon A, Morilla R, Atkinson S, et al. The leukemic presentation of mantle-cell lymphoma: disease features and prognostic factors in 58 patients. Leuk Lymphoma. United States. 2004;45:2007\u201315.","journal-title":"Leuk Lymphoma"},{"key":"1094_CR34","doi-asserted-by":"publisher","first-page":"413","DOI":"10.1182\/blood-2018-03-838136","volume":"132","author":"G Clot","year":"2018","unstructured":"\u2022\u2022 Clot G, Jares P, Gin\u00e9 E, Navarro A, Royo C, Pinyol M, et al. A gene signature that distinguishes conventional and leukemic nonnodal mantle cell lymphoma helps predict outcome. Blood. 2018;132:413\u201322 The authors developed a novel, 16 gene expression assay to differentiate cMCL from LV-MCL. Both subsets had distinct clinical and cytogenetic features; however, there is significant overlap between cMCL and LV-MCL that limits the use of a single biomarker. A cohort of LV-MCL with TP53 aberrations had stable disease without need for therapy, further demonstrating the genetic complexity of MCL.","journal-title":"Blood"},{"key":"1094_CR35","doi-asserted-by":"publisher","first-page":"38","DOI":"10.1016\/j.anndiagpath.2019.05.004","volume":"41","author":"A Sakhdari","year":"2019","unstructured":"Sakhdari A, Ok CY, Patel KP, Kanagal-Shamanna R, Yin CC, Zuo Z, et al. TP53 mutations are common in mantle cell lymphoma, including the indolent leukemic non-nodal variant. Ann Diagn Pathol. United States. 2019;41:38\u201342.","journal-title":"Ann Diagn Pathol"},{"key":"1094_CR36","doi-asserted-by":"publisher","first-page":"754","DOI":"10.3324\/haematol.2019.219543","volume":"105","author":"B Federmann","year":"2020","unstructured":"Federmann B, Frauenfeld L, Pertsch H, Borgmann V, Steinhilber J, Bonzheim I, et al. Highly sensitive and specific in situ hybridization assay for quantification of SOX11 mRNA in mantle cell lymphoma reveals association of TP53 mutations with negative and low SOX11 expression. Haematologica. 2020;105:754\u201364.","journal-title":"Haematologica."},{"key":"1094_CR37","first-page":"1209","volume":"27","author":"P Martin","year":"2009","unstructured":"Martin P, Chadburn A, Christos P, Weil K, Furman RR, Ruan J, et al. Outcome of deferred initial therapy in mantle-cell lymphoma. J Clin Oncol Off J Am Soc Clin Oncol. United States. 2009;27:1209\u201313.","journal-title":"United States"},{"key":"1094_CR38","doi-asserted-by":"publisher","first-page":"2489","DOI":"10.1093\/annonc\/mdx333","volume":"28","author":"P Abrisqueta","year":"2017","unstructured":"\u2022\u2022 Abrisqueta P, Scott DW, Slack GW, Steidl C, Mottok A, Gascoyne RD, et al. Observation as the initial management strategy in patients with mantle cell lymphoma. Ann Oncol. 2017;28:2489\u201395 Patients who had treatment deferred had significantly longer overall survival than those who are treated early, demonstrating that a subset of patients can be safely observed. In this study, 21% of patients in the observation group had LV-MCL.","journal-title":"Ann Oncol"},{"key":"1094_CR39","doi-asserted-by":"publisher","first-page":"2356","DOI":"10.1002\/cncr.30068","volume":"122","author":"JB Cohen","year":"2016","unstructured":"Cohen JB, Han X, Jemal A, Ward EM, Flowers CR. Deferred therapy is associated with improved overall survival in patients with newly diagnosed mantle cell lymphoma. Cancer. United States. 2016;122:2356\u201363.","journal-title":"Cancer"},{"key":"1094_CR40","doi-asserted-by":"publisher","first-page":"2745","DOI":"10.1182\/blood-2017-09-806398","volume":"131","author":"M Hallek","year":"2018","unstructured":"Hallek M, Cheson BD, Catovsky D, Caligaris-Cappio F, Dighiero G, Dohner H, et al. iwCLL guidelines for diagnosis, indications for treatment, response assessment, and supportive management of CLL. Blood. United States. 2018;131:2745\u201360.","journal-title":"Blood"},{"key":"1094_CR41","doi-asserted-by":"publisher","first-page":"604","DOI":"10.1182\/blood-2015-02-628792","volume":"126","author":"M-H Delfau-Larue","year":"2015","unstructured":"Delfau-Larue M-H, Klapper W, Berger F, Jardin F, Briere J, Salles G, et al. High-dose cytarabine does not overcome the adverse prognostic value of CDKN2A and TP53 deletions in mantle cell lymphoma. Blood. United States. 2015;126:604\u201311.","journal-title":"Blood"},{"key":"1094_CR42","doi-asserted-by":"crossref","unstructured":"\u2022\u2022 Eskelund CW, Dahl C, Hansen JW, Westman M, Kolstad A, Pedersen LB, et al. TP53 mutations identify younger mantle cell lymphoma patients who do not benefit from intensive chemoimmunotherapy. Blood. United States; 2017;130:1903\u201310. This study demonstrates that TP53-mutated MCL is typically chemotherapy-refractory, and proposes that frontline clinical trials with novel agents should be considered for these patients.","DOI":"10.1182\/blood-2017-04-779736"},{"key":"1094_CR43","first-page":"851","volume":"134","author":"CS Tam","year":"2019","unstructured":"Tam CS, Trotman J, Opat S, Burger JA, Cull G, Gottlieb D, et al. Phase 1 study of the selective BTK inhibitor zanubrutinib in B-cell malignancies and safety and efficacy evaluation in CLL. Blood. United States. 2019;134:851\u20139.","journal-title":"Blood. United States"},{"key":"1094_CR44","doi-asserted-by":"crossref","unstructured":"\u2022\u2022 Tam CS, Anderson MA, Pott C, Agarwal R, Handunnetti S, Hicks RJ, et al. Ibrutinib plus venetoclax for the treatment of mantle-cell lymphoma. N Engl J Med. United States; 2018;378:1211\u201323. Patients with relapsed or refractory MCL had high rates of complete response when treated with combined ibrutinib plus venetoclax. In this cohort, half of patients had TP53 mutations and most had progressed after prior autologous stem cell transplantation.","DOI":"10.1056\/NEJMoa1715519"},{"key":"1094_CR45","doi-asserted-by":"publisher","first-page":"507","DOI":"10.1056\/NEJMoa1306220","volume":"369","author":"ML Wang","year":"2013","unstructured":"Wang ML, Rule S, Martin P, Goy A, Auer R, Kahl BS, et al. Targeting BTK with ibrutinib in relapsed or refractory mantle-cell lymphoma. N Engl J Med. United States. 2013;369:507\u201316.","journal-title":"N Engl J Med"}],"container-title":["Current Oncology Reports"],"original-title":[],"language":"en","link":[{"URL":"https:\/\/link.springer.com\/content\/pdf\/10.1007\/s11912-021-01094-y.pdf","content-type":"application\/pdf","content-version":"vor","intended-application":"text-mining"},{"URL":"https:\/\/link.springer.com\/article\/10.1007\/s11912-021-01094-y\/fulltext.html","content-type":"text\/html","content-version":"vor","intended-application":"text-mining"},{"URL":"https:\/\/link.springer.com\/content\/pdf\/10.1007\/s11912-021-01094-y.pdf","content-type":"application\/pdf","content-version":"vor","intended-application":"similarity-checking"}],"deposited":{"date-parts":[[2021,8,7]],"date-time":"2021-08-07T14:48:59Z","timestamp":1628347739000},"score":1,"resource":{"primary":{"URL":"https:\/\/link.springer.com\/10.1007\/s11912-021-01094-y"}},"subtitle":[],"short-title":[],"issued":{"date-parts":[[2021,7,16]]},"references-count":45,"journal-issue":{"issue":"9","published-print":{"date-parts":[[2021,9]]}},"alternative-id":["1094"],"URL":"https:\/\/doi.org\/10.1007\/s11912-021-01094-y","relation":{},"ISSN":["1523-3790","1534-6269"],"issn-type":[{"value":"1523-3790","type":"print"},{"value":"1534-6269","type":"electronic"}],"subject":[],"published":{"date-parts":[[2021,7,16]]},"assertion":[{"value":"20 May 2021","order":1,"name":"accepted","label":"Accepted","group":{"name":"ArticleHistory","label":"Article History"}},{"value":"16 July 2021","order":2,"name":"first_online","label":"First Online","group":{"name":"ArticleHistory","label":"Article History"}},{"order":1,"name":"Ethics","group":{"name":"EthicsHeading","label":"Declarations"}},{"value":"Krista M. Isaac declares that she has no conflict of interest. Craig A. Portell has received research funding from AbbVie, BeiGene, Kite\/Gilead, Genentech, TG Therapeutics, Acerta, Infinity Pharmaceuticals\/Verastem Oncology, and VelosBio and has received compensation from Amgen, BeiGene, Janssen, Pharmacyclics, Kite Pharma\/Gilead Sciences, MorphoSys, and Genentech for service as a consultant. Michael E. Williams has received clinical trial support (paid to the University of Virginia) from Janssen, Pharmacyclics, TG Therapeutics, Gilead Sciences, and Celgene; has contributed to a lymphoma registry sponsored by Allos Therapeutics; has received speaker\u2019s honoraria from Xian Janssen Pharmaceutical Ltd.; and has received compensation from Celgene, Gilead Sciences, TG Therapeutics, AbbVie, Kite Pharma, Juno Pharmaceuticals, Verastem Oncology, Seattle Genetics, Sandoz, AstraZeneca, and Kymera Therapeutics for participation on advisory boards.","order":2,"name":"Ethics","group":{"name":"EthicsHeading","label":"Conflict of Interest"}}],"article-number":"102"}}